Breaking News Instant updates and real-time market news.

ABEO

Abeona Therapeutics

$3.00

0.25 (9.09%)

08:46
12/09/19
12/09
08:46
12/09/19
08:46

Abeona Therapeutics cleared to initiate EB-101 Phase 3 clinical trial

Abeona Therapeutics announced that the FDA has removed its clinical hold and provided clearance to proceed with the VIITAL study, the company's pivotal Phase 3 clinical trial evaluating EB-101 for the treatment of recessive dystrophic epidermolysis bullosa, or RDEB. The FDA removed the clinical hold following the company's submission of additional data points on transport stability of EB-101 to clinical sites. Abeona expects to initiate the VIITAL study in first quarter of 2020.

ABEO Abeona Therapeutics
$3.00

0.25 (9.09%)

08/12/19
CANT
08/12/19
DOWNGRADE
Target $2
CANT
Neutral
Cantor Fitzgerald downgrades Abeona, slashes price target to $2 from $29
As previously reported, Cantor Fitzgerald analyst Elemer Piros downgraded Abeona Therapeutics to Neutral from Overweight and slashed his price target on the shares to $2 from $29 following the company's Q2 earnings report. He remains wary of competition for the company's mucopolysaccharidosis IIIA/B and dystrophic epidermolysis bullosa programs and believes Abeona will need to raise money in the next 12 months, Piros tells investors.
08/13/19
RBCM
08/13/19
NO CHANGE
Target $16
RBCM
Outperform
Abeona Therapeutics price target lowered to $16 from $23 at RBC Capital
RBC Capital analyst Kennen MacKay lowered his price target on Abeona Therapeutics to $16 after its Q2 earnings miss, also reflecting the delay in its EB-101 program and changing in his valuation methodology to discounted cash flow model. The analyst is keeping his Outperform rating on the stock longer term however with a positive view of its in-house manufacturing capabilities and the clinical profile of EB-101.
08/15/19
MAXM
08/15/19
DOWNGRADE
MAXM
Hold
Abeona Therapeutics downgraded to Hold from Buy at Maxim
Maxim analyst Jason McCarthy downgraded Abeona Therapeutics to Hold from Buy without a price target. At the current burn rate and the Viital phase 3 study not expected to initiate until Q4, Abeona is likely going to need to raise capital, McCarthy tells investors in a research note. The analyst prefers to wait on the sidelines pending clarity on the RDEB trial and additional larger data sets from the Sanfilippo programs.
08/15/19
08/15/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Evergy (EVRG) downgraded to Market Perform from Outperform at Wells Fargo with analyst Sarah Akers citing valuation. 2. Host Hotels (HST) and Pebblebrook Hotel (PEB) downgraded to Neutral from Buy at BTIG. 3. Toronto-Dominion (TD) downgraded to Neutral from Buy at BofA/Merrill with analyst Ebrahim Poonawala citing the recent outperformance of Canadian banks relative to their global banking peers, the analyst is turning more cautious on the group. 4. Urban Outfitters (URBN) downgraded to Neutral from Buy at B. Riley FBR with analyst Susan Anderson saying on its Q1 earnings call, management said they expected sales will start to improve with new back-to-school product in July and into August. 5. Abeona Therapeutics (ABEO) downgraded to Hold from Buy at Maxim with analyst Jason McCarthy saying at the current burn rate and the Viital phase 3 study not expected to initiate until Q4, Abeona is likely going to need to raise capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

VERU

Veru

$4.19

0.07 (1.70%)

07:25
01/21/20
01/21
07:25
01/21/20
07:25
Recommendations
Veru analyst commentary  »

Veru price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUAN

Nuance

$19.74

-0.02 (-0.10%)

07:24
01/21/20
01/21
07:24
01/21/20
07:24
Hot Stocks
Nuance announces Dragon Medical One availability in France, Belgium, Netherlands »

Nuance Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 05

    Feb

MRSN

Mersana Therapeutics

$8.05

0.42 (5.50%)

07:23
01/21/20
01/21
07:23
01/21/20
07:23
Recommendations
Mersana Therapeutics analyst commentary  »

Mersana Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EOG

EOG Resources

$85.35

-1.66 (-1.91%)

07:22
01/21/20
01/21
07:22
01/21/20
07:22
Upgrade
EOG Resources rating change  »

EOG Resources upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

KMDA

Kamada

$6.62

0.09 (1.38%)

07:21
01/21/20
01/21
07:21
01/21/20
07:21
Hot Stocks
Kamada announces $25M private placement with FIMI Opportunity Fund »

Kamada announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LTHM

Livent

$8.90

0.05 (0.57%)

07:21
01/21/20
01/21
07:21
01/21/20
07:21
Downgrade
Livent rating change  »

Livent downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KVHI

KVH Industries

$10.91

0.05 (0.46%)

, LMT

Lockheed Martin

$425.62

-0.055 (-0.01%)

07:20
01/21/20
01/21
07:20
01/21/20
07:20
Hot Stocks
Lockheed Martin selects KVH fiber optic gyro for infrared search, track system »

KVH Industries (KVHI)…

KVHI

KVH Industries

$10.91

0.05 (0.46%)

LMT

Lockheed Martin

$425.62

-0.055 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

BIDU

Baidu

$139.64

0.2 (0.14%)

07:18
01/21/20
01/21
07:18
01/21/20
07:18
Recommendations
Baidu analyst commentary  »

Baidu price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

DIS

Disney

$144.25

-0.85 (-0.59%)

07:18
01/21/20
01/21
07:18
01/21/20
07:18
Hot Stocks
Disney+ moves up EMEA launch date to March 24 »

Disney's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Feb

RDHL

RedHill Biopharma

$6.16

0.11 (1.82%)

07:18
01/21/20
01/21
07:18
01/21/20
07:18
Hot Stocks
RedHill Biopharma discontinues promotion of Donnatal, EnteraGam »

RedHill Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KSU

Kansas City Southern

$166.57

4.77 (2.95%)

07:17
01/21/20
01/21
07:17
01/21/20
07:17
Initiation
Kansas City Southern initiated  »

Benchmark starts Kansas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BGNE

BeiGene

$170.73

2.85 (1.70%)

07:16
01/21/20
01/21
07:16
01/21/20
07:16
Hot Stocks
BeiGene says Phase 3 trial of tislelizumab meets primary endpoint »

BeiGene announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

CSX

CSX

$76.36

-0.39 (-0.51%)

07:16
01/21/20
01/21
07:16
01/21/20
07:16
Initiation
CSX initiated  »

Benchmark doesn't…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PDD

Pinduoduo

$39.43

-0.07 (-0.18%)

07:15
01/21/20
01/21
07:15
01/21/20
07:15
Recommendations
Pinduoduo analyst commentary  »

Pinduoduo price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MA

MasterCard

$323.60

3.36 (1.05%)

07:15
01/21/20
01/21
07:15
01/21/20
07:15
Initiation
MasterCard initiated  »

MasterCard initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

V

Visa

$204.71

3.765 (1.87%)

07:14
01/21/20
01/21
07:14
01/21/20
07:14
Initiation
Visa initiated  »

Visa initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 30

    Jan

  • 11

    Feb

ETON

Eton Pharmaceuticals

$7.14

-0.3 (-4.03%)

07:14
01/21/20
01/21
07:14
01/21/20
07:14
Hot Stocks
Eton Pharmaceuticals, Xellia announce Biorphen co-promotion agreement »

Eton Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Mar

MYGN

Myriad Genetics

$28.71

-0.21 (-0.73%)

, AZN

AstraZeneca

$51.34

0.84 (1.66%)

07:13
01/21/20
01/21
07:13
01/21/20
07:13
Hot Stocks
Myriad Genetics submits sPMA for BRACAnalysis CDx as companion diagnostic »

Myriad Genetics (MYGN)…

MYGN

Myriad Genetics

$28.71

-0.21 (-0.73%)

AZN

AstraZeneca

$51.34

0.84 (1.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 06

    Feb

  • 13

    Feb

BABA

Alibaba

$227.41

3.53 (1.58%)

07:12
01/21/20
01/21
07:12
01/21/20
07:12
Recommendations
Alibaba analyst commentary  »

Alibaba price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

  • 13

    Feb

SWTX

SpringsWorks Therapeutics

$35.77

0.07 (0.20%)

07:12
01/21/20
01/21
07:12
01/21/20
07:12
Recommendations
SpringsWorks Therapeutics analyst commentary  »

SpringsWorks price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEGA

Pegasystems

$86.47

0.64 (0.75%)

07:12
01/21/20
01/21
07:12
01/21/20
07:12
Initiation
Pegasystems initiated  »

Pegasystems initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 05

    Mar

  • 10

    Mar

GTHX

G1 Therapeutics

$25.36

-0.42 (-1.63%)

07:11
01/21/20
01/21
07:11
01/21/20
07:11
Recommendations
G1 Therapeutics analyst commentary  »

G1 Therapeutics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QD

Qudian

$3.51

-0.035 (-0.99%)

07:11
01/21/20
01/21
07:11
01/21/20
07:11
Downgrade
Qudian rating change  »

Qudian downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AG

First Majestic

$10.53

-0.515 (-4.66%)

07:11
01/21/20
01/21
07:11
01/21/20
07:11
Hot Stocks
First Majestic to install HIG mill technology at San Dimas, La Encantada mines »

As a result of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 22

    Jan

AG

First Majestic

$10.53

-0.515 (-4.66%)

07:10
01/21/20
01/21
07:10
01/21/20
07:10
Hot Stocks
First Majestic to invest $171.5M on capex in 2020 »

In 2020, the Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 22

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.